Amgen Inc. CDR

Amgen Inc. Canadian Depositary Receipt (CDR) is a financial instrument that allows investors to gain exposure to the shares of Amgen Inc., a leading biotechnology company headquartered in Thousand Oaks and founded in 1980, through a security denominated in Canadian dollars. As an innovative biotechnology firm, Amgen Inc. specializes in developing and manufacturing biopharmaceuticals targeting serious illnesses, with a focus on healthcare technology and therapeutic advancements within the biotechnology sector. The Amgen Inc. CDR is CAD-hedged, offering investors protection against fluctuations between the Canadian and U.S. currencies, making it particularly attractive to Canadian investors seeking simplified access to global equities without the complexities of direct foreign investment. Utilizing a variable CDR ratio to match the underlying share value, this instrument provides an accessible entry point for diversified participation in the healthcare industry, while maintaining streamlined trading and reporting in the Canadian market.